Thus, treatment with anthracycline-based chemotherapy appears to be associated with a very small benefit in both TIMP-1 high and low patients but it should be kept in mind that the anthracycline-treated subgroup is characterized by very poor prognostic features (larger tumors, many tumor-involved lymph nodes, Table 1). This evidence concerns the gene TIMP1 and neoplasm.